Stock ZEG ASTRAZENECA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials AstraZeneca PLC Deutsche Boerse AG

Equities

ZEG

GB0009895292

Pharmaceuticals

Real-time Estimate Tradegate
Other stock markets
 10:47:24 2024-07-16 am EDT 		5-day change 1st Jan Change
143.8 EUR -0.16% Intraday chart for AstraZeneca PLC +1.27% +17.89%
Jul. 15 Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast... Our Logo
Jul. 15 AstraZeneca: acquisition of Amolyt Pharma finalized CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 132,331 131,461 181,878 210,243 209,128 243,647 - -
Enterprise Value (EV) 1 144,340 143,328 206,261 233,166 231,638 264,639 258,168 251,043
P/E ratio 97.9 x 41 x 1,468 x 64.3 x 35.4 x 27.9 x 23.2 x 20.6 x
Yield 2.78% 2.8% 2.44% 2.14% 2.15% 1.96% 2.07% 2.15%
Capitalization / Revenue 5.43 x 4.94 x 4.86 x 4.74 x 4.57 x 4.72 x 4.39 x 4.15 x
EV / Revenue 5.92 x 5.38 x 5.51 x 5.26 x 5.06 x 5.13 x 4.65 x 4.27 x
EV / EBITDA 21.6 x 17.2 x 27.2 x 25.2 x 17.1 x 14.9 x 12.8 x 11.4 x
EV / FCF 72.5 x 37.3 x 42.3 x 26.7 x 25.8 x 30.7 x 21.9 x 18.3 x
FCF Yield 1.38% 2.68% 2.36% 3.74% 3.88% 3.26% 4.56% 5.46%
Price to Book 10 x 8.41 x 4.24 x 5.67 x 5.38 x 5.86 x 5.23 x 4.59 x
Nbr of stocks (in thousands) 1,311,913 1,312,660 1,549,159 1,549,528 1,549,926 1,550,268 - -
Reference price 2 100.9 100.1 117.4 135.7 134.9 157.2 157.2 157.2
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 24,384 26,617 37,417 44,351 45,811 51,615 55,488 58,741
EBITDA 1 6,686 8,311 7,586 9,237 13,580 17,797 20,117 22,064
EBIT 1 6,436 7,340 9,928 13,350 14,534 16,876 19,133 20,839
Operating Margin 26.39% 27.58% 26.53% 30.1% 31.73% 32.7% 34.48% 35.48%
Earnings before Tax (EBT) 1 1,548 3,916 -265 2,501 6,899 11,090 13,178 14,793
Net income 1 1,335 3,196 112 3,288 5,961 8,732 10,464 11,730
Net margin 5.47% 12.01% 0.3% 7.41% 13.01% 16.92% 18.86% 19.97%
EPS 2 1.030 2.440 0.0800 2.110 3.810 5.640 6.764 7.635
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,627 11,772 13,716
FCF margin 8.16% 14.42% 13.02% 19.65% 19.61% 16.71% 21.22% 23.35%
FCF Conversion (EBITDA) 29.76% 46.18% 64.22% 94.37% 66.16% 48.48% 58.52% 62.16%
FCF Conversion (Net income) 149.06% 120.09% 4,350% 265.12% 150.71% 98.8% 112.51% 116.93%
Dividend per Share 2 2.800 2.800 2.870 2.900 2.900 3.083 3.249 3.380
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - 12,011 - 11,390 10,771 - 10,982 11,207 - 10,879 11,416 11,492 12,024 12,679 12,551 12,560 12,963 13,516 13,410 13,685
EBITDA 1 - - - 1,900 - 2,187 1,896 - 2,579 2,574 - - 3,732 - - - 4,305 - 4,380 5,401 - -
EBIT 1 - - - 3,318 - 3,961 3,365 - 3,413 2,610 - 3,946 4,291 3,545 2,752 4,310 3,986 4,052 4,356 4,054 - -
Operating Margin - - - 27.62% - 34.78% 31.24% - 31.08% 23.29% - 36.27% 37.59% 30.85% 22.89% 33.99% 31.75% 32.26% 33.6% 29.99% - -
Earnings before Tax (EBT) 1 - - - -636 - 553 247 - 922 778 - 2,262 2,088 1,652 897 2,800 2,395 - 2,714 3,057 - -
Net income 1 - - - -347 - 386 360 - 1,640 901 - 1,803 1,818 1,378 959 2,179 2,080 - 2,426 2,522 - -
Net margin - - - -2.89% - 3.39% 3.34% - 14.93% 8.04% - 16.57% 15.93% 11.99% 7.98% 17.19% 16.57% - 18.72% 18.66% - -
EPS 2 - - - -0.2200 - 0.2500 0.2300 - 1.050 0.5800 - 1.160 1.170 0.8900 0.6200 1.410 1.331 - 1.555 1.619 - -
Dividend per Share 2 0.9000 1.900 0.9000 1.970 1.970 - 0.9300 0.9300 - 1.970 1.970 - 0.9300 - 1.970 - 0.8875 - 0.7750 1.438 0.8750 0.8750
Announcement Date 7/30/20 2/11/21 7/29/21 2/10/22 2/10/22 4/29/22 7/29/22 7/29/22 11/10/22 2/9/23 2/9/23 4/27/23 7/28/23 11/9/23 2/8/24 4/25/24 - - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,009 11,867 24,383 22,923 22,510 20,992 14,521 7,396
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.796 x 1.428 x 3.214 x 2.482 x 1.658 x 1.18 x 0.7218 x 0.3352 x
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,627 11,772 13,716
ROE (net income / shareholders' equity) 35.6% 36.7% 27.5% 27.2% 29.8% 29.7% 31.1% 30.3%
ROA (Net income/ Total Assets) 2.19% 4.99% 8.77% 3.26% 11.5% 9.56% 10.7% 11.7%
Assets 1 61,015 64,053 1,277 100,924 51,935 91,348 97,378 99,918
Book Value Per Share 2 10.10 11.90 27.70 23.90 25.10 26.80 30.10 34.20
Cash Flow per Share 2 2.280 3.660 4.180 6.290 6.620 8.520 10.40 11.50
Capex 1 979 961 1,091 1,091 1,361 1,988 1,988 2,007
Capex / Sales 4.01% 3.61% 2.92% 2.46% 2.97% 3.85% 3.58% 3.42%
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for AstraZeneca PLC

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
157.2 USD
Average target price
177.6 USD
Spread / Average Target
+13.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+63.33% 856B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.34% 631B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.04% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.82% 325B
ABBVIE INC. Stock AbbVie Inc.
+8.98% 297B
ROCHE HOLDING AG Stock Roche Holding AG
+5.73% 234B
NOVARTIS AG Stock Novartis AG
+16.67% 226B
AMGEN INC. Stock Amgen Inc.
+15.85% 177B
PFIZER, INC. Stock Pfizer, Inc.
+2.15% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. ZEG Stock
  5. Financials AstraZeneca PLC